Group of Dr. Traube - Faculty for Chemistry and Pharmacy

Traube Research Group

Welcome to the Traube Research Group!

We are interested in how epigenetic information is regulated during development and disease. To study these processes, we are pursuing an interdisciplinary approach with methods from molecular cell biology, biochemistry, chemical biology, analytical chemistry and computational biology. Being located at the High-Tech Campus Großhadern of the LMU Munich at the newly opened Institute for Chemical Epigenetics (ICE-M), we have access to state of the art mass spectrometry, flow cytometry, sequencing and imaging facilities. Although the group has only been established since the fall of 2021, we are already well embedded in several cross-university and interdisciplinary research programs and we were already successful to acquire independent funding. We also maintain strong links with the Chemistry Department of the Technical University of Munich, the Max-Planck-Institute for Biochemistry and the University Hospital of the LMU (Klinikum Großhadern).

For more details about our research projects, please check out our Research subpage.


We are proud that our study "Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line" is now published in Clinical Epigenetics!

August 2022

Franziska becomes TUM Junior Fellow!


We are proud to announce that the group will be funded from August 2022 on by the Liebig Fellowship of the Fonds der Chemischen Industrie and will be part of the new Department of Bioscience at the Technische Universität München (TUM)! The Liebig Fellowship is granted at an early career stage to promote independent research in the field of chemistry and related fields. The fellowship is granted for the research topic "Understanding and targeting the cancer epigenome by interfering with DNA (hydroxy)methylation and α-ketoglutarate metabolism".


The study "Suppression of SARS-CoV-2 Replication with Stabilized and Click-Chemistry Modified siRNAs" of the Carell group and Keppler group with Franziska as a first author is now accepted by Angewandte Chemie International Edition!


We are happy that CRC1309 starts its second funding period to which our group will contribute with the project C08 "Metabolic control of the epigenetic landscape". Franziska will also support the IRTG team and help with data management. For more information, please visit the CRC1309 homepage, which is updated regularly.


Our study with the Carell group about a stabilized carbocyclic decitabine analogue as an epigenetic anti-cancer treatment is published in Chemistry - A European Journal.


Our preprint "Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line" is now online at bioRxiv.


Franziska received a fellowship from the Daimler and Benz Foundation for the project "Mechanistic insights into the mode of action of azanucleosides as anti-cancer treatment".